Anthony R. Mato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Anthony R. Mato has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Alison Wakoff Loren
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
3 shared publications - Edward Allen Stadtmauer
Division of Hematology Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, USA
3 shared publications - Daniel Jeffrey Landsburg
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
2 shared publications - Jakub Svoboda
Abramson Cancer Center Perelman School of Medicine, University of Pennsylvania Philadelphia Pennsylvania USA
2 shared publications - Stephen J. Schuster
Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 shared publications - Steven Michael Bair
University of Colorado School of Medicine, Aurora, Colorado, United States
2 shared publications
Latest Publications
- Open Access
- 5 June 2018
- Published by Wiley in British Journal of Haematology
- Vol. 182 (4) , 504-512
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
Summary: Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1–12), 18% and 79% of evaluable patients had del(11q) or unmutated IGHV, respectively. With a median follow‐up of 28 months, overall response rate was 85% and estimated 30‐month progression‐free and overall survival rates were 57% [95% confidence interval (CI) 50–64] and 69% (95% CI 61–75), respectively. Patients with normal lactate dehydrogenase or no bulky disease had the most favourable survival outcomes. Sustained haematological improvements in haemoglobin, platelet count and absolute neutrophil count occurred in 61%, 67% and 70% of patients with baseline cytopenias, respectively. New onset severe cytopenias and infections decreased in frequency over time. Progression‐free and overall survival with ibrutinib surpass those of other therapies for patients with del(17p) CLL/SLL. These results provide further evidence of the robust clinical activity of ibrutinib in difficult‐to‐treat CLL/SLL populations.
- 5 June 2018
- Published by Wiley in British Journal of Haematology
- Vol. 182 (4) , 504-512
Open AccessEvaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
Summary: Patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) with deletion 17p [del(17p)] have poor outcomes with chemoimmunotherapy. Ibrutinib is indicated for the treatment of CLL/SLL, including del(17p) CLL/SLL, and allows for treatment without chemotherapy. This integrated analysis was performed to evaluate outcomes in 230 patients with relapsed/refractory del(17p) CLL/SLL from three ibrutinib studies. With a median of 2 prior therapies (range, 1–12), 18% and 79% of evaluable patients had del(11q) or unmutated IGHV, respectively. With a median follow‐up of 28 months, overall response rate was 85% and estimated 30‐month progression‐free and overall survival rates were 57% [95% confidence interval (CI) 50–64] and 69% (95% CI 61–75), respectively. Patients with normal lactate dehydrogenase or no bulky disease had the most favourable survival outcomes. Sustained haematological improvements in haemoglobin, platelet count and absolute neutrophil count occurred in 61%, 67% and 70% of patients with baseline cytopenias, respectively. New onset severe cytopenias and infections decreased in frequency over time. Progression‐free and overall survival with ibrutinib surpass those of other therapies for patients with del(17p) CLL/SLL. These results provide further evidence of the robust clinical activity of ibrutinib in difficult‐to‐treat CLL/SLL populations.
- 1 September 2017
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 17 (9) , 563-568
Emerging Strategies in Treating Double Hit Lymphomas
- 1 September 2017
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 17 (9) , 563-568
Emerging Strategies in Treating Double Hit Lymphomas
- 9 June 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , 879-884
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis
Patients with relapsed/refractory Hodgkin lymphoma (RR‐HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR‐HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR‐HL with relapse post‐ASCT. Treatment with novel agents (including brentuximab vedotin) was associated with significant improvement in median overall survival (OS) compared to patients who did not receive novel agents (85.6 vs 17.1 months;P < .001). Additional factors associated with improved OS in univariate analysis include treatment with radiation therapy post‐ASCT (34.1 vs 17.0 months;P = .015), chemosensitivity (i.e., relapsed compared to primary refractory disease; 51.8 vs 25.6 months; p = 0.013), initial response to ASCT (i.e., CR/PR compared to SD/PD; 46.1 vs 20.4 months;P = .011), and transplantation in 2010 and later compared to prior to 2010 (not reached vs 24.5 months;P = .025). The current study demonstrates markedly improved OS in RR‐HL patients treated with novel therapeutics and lends “real world” credence to the role of these agents in improving outcomes in the current era.
- 9 June 2017
- Published by Wiley in American Journal of Hematology
- Vol. 92 (9) , 879-884
Outcomes of patients with relapsed/refractory Hodgkin lymphoma progressing after autologous stem cell transplant in the current era of novel therapeutics: A retrospective analysis
Patients with relapsed/refractory Hodgkin lymphoma (RR‐HL) who progress or relapse following autologous stem cell transplantation (ASCT) have historically had a poor prognosis. Several novel agents, particularly brentuximab vedotin, have shown efficacy in this setting. However, there remains a paucity of data characterizing outcomes outside of clinical trials and how these novel agents have impacted prognosis in general population of patients with RR‐HL. Here, we conducted a retrospective analysis to evaluate outcomes in 87 patients with RR‐HL with relapse post‐ASCT. Treatment with novel agents (including brentuximab vedotin) was associated with significant improvement in median overall survival (OS) compared to patients who did not receive novel agents (85.6 vs 17.1 months;P < .001). Additional factors associated with improved OS in univariate analysis include treatment with radiation therapy post‐ASCT (34.1 vs 17.0 months;P = .015), chemosensitivity (i.e., relapsed compared to primary refractory disease; 51.8 vs 25.6 months; p = 0.013), initial response to ASCT (i.e., CR/PR compared to SD/PD; 46.1 vs 20.4 months;P = .011), and transplantation in 2010 and later compared to prior to 2010 (not reached vs 24.5 months;P = .025). The current study demonstrates markedly improved OS in RR‐HL patients treated with novel therapeutics and lends “real world” credence to the role of these agents in improving outcomes in the current era.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 2543
Outcomes in patients with relapsed/refractory Hodgkin lymphoma (RR-HL) with progression after autologous stem cell transplantation in the current era of novel therapeutics.
2543 Background: Patients (pts) with RR-HL who progress or relapse following autologous stem cell transplantation (ASCT) have a poor prognosis, with a historical median overall survival (OS) of 27 months (Crump, Blood 2008). More recently, these pts have been treated with novel therapies, particularly brentuximab vedotin (BV). We hypothesized that these agents have contributed to greater OS in this population. Methods: We conducted a retrospective study of all pts with RR-HL who underwent ASCT at the Univ. of Pennsylvania between 2004 and 2014. Therapy was given at discretion of the treating physician and reported data were collected through 10/2015. The primary endpoint was median OS from post-ASCT relapse. Results: Of 136 pts, 69 (50.7%) relapsed or progressed after ASCT. Median age was 37.5 years. Of pts who relapsed post-ASCT, 27 (40%) were exposed to at least one or more novel agents after relapse including 23 (34%) pts who received BV, 6 (9%) nivolumab, 5 (7%) lenalidomide, and 4 (6%) panobinostat. Median OS and follow-up were 34 and 72 months, respectively. Pts treated with novel agents had significantly prolonged OS compared to pts treated with conventional chemotherapy only (86 vs 22 months; p = 0.007). Other factors associated with improved OS in univariate analysis included age at relapse, response to ASCT, and radiation treatment (XRT) after post-ASCT relapse. Conclusions: Pts with RR-HL post-ASCT who are treated with novel agents may achieve prolonged OS when compared to chemotherapy alone. These results suggest improved outcomes when matched to historical controls and are likely a more accurate estimate of OS in the current era of expanded therapeutic options.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 2543
Outcomes in patients with relapsed/refractory Hodgkin lymphoma (RR-HL) with progression after autologous stem cell transplantation in the current era of novel therapeutics.
2543 Background: Patients (pts) with RR-HL who progress or relapse following autologous stem cell transplantation (ASCT) have a poor prognosis, with a historical median overall survival (OS) of 27 months (Crump, Blood 2008). More recently, these pts have been treated with novel therapies, particularly brentuximab vedotin (BV). We hypothesized that these agents have contributed to greater OS in this population. Methods: We conducted a retrospective study of all pts with RR-HL who underwent ASCT at the Univ. of Pennsylvania between 2004 and 2014. Therapy was given at discretion of the treating physician and reported data were collected through 10/2015. The primary endpoint was median OS from post-ASCT relapse. Results: Of 136 pts, 69 (50.7%) relapsed or progressed after ASCT. Median age was 37.5 years. Of pts who relapsed post-ASCT, 27 (40%) were exposed to at least one or more novel agents after relapse including 23 (34%) pts who received BV, 6 (9%) nivolumab, 5 (7%) lenalidomide, and 4 (6%) panobinostat. Median OS and follow-up were 34 and 72 months, respectively. Pts treated with novel agents had significantly prolonged OS compared to pts treated with conventional chemotherapy only (86 vs 22 months; p = 0.007). Other factors associated with improved OS in univariate analysis included age at relapse, response to ASCT, and radiation treatment (XRT) after post-ASCT relapse. Conclusions: Pts with RR-HL post-ASCT who are treated with novel agents may achieve prolonged OS when compared to chemotherapy alone. These results suggest improved outcomes when matched to historical controls and are likely a more accurate estimate of OS in the current era of expanded therapeutic options.
- Open Access
- 25 March 2016
- Published by Wiley in American Journal of Hematology
- Vol. 91 (7) , 672-676
Autologous stem cell transplantation in first complete remission may not extend progression‐free survival in patients with peripheral T cell lymphomas
Patients with peripheral T cell lymphomas (PTCL) generally have a poor prognosis when treated with conventional chemotherapy. Consolidation with autologous stem cell transplantation (ASCT) has been reported to improve progression‐free survival. However, these studies have not compared consolidative ASCT with active observation in patients with PTCL achieving first complete remission (CR1) following induction chemotherapy. We conducted a retrospective analysis of PTCL patients treated at the University of Pennsylvania between 1/1/2007 and 12/31/2014. Patients with cutaneous T cell lymphoma, concurrent B cell lymphomas, and anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma (ALK‐positive ALCL) were excluded from the study. We compared progression‐free survival for patients who underwent ASCT in CR1 following CHOP‐like induction regimens and patients who underwent active observation during CR1. 48 patients met all inclusion and exclusion criteria and underwent either active observation (28 patients) or consolidative ASCT (20 patients) in CR1. The 1‐year cumulative incidence of relapse in the observation and ASCT groups was 50% (95% confidence interval [CI]: 30–67%) and 46% (95% CI: 23–67%), respectively (P = 0.55). Median progression‐free survival in the observation and ASCT groups was 15.8 and 12.8 months, respectively (log rank, P = 0.79). Estimated 3‐year progression‐free survival in the observation and ASCT groups was 37 and 41%, respectively. In conclusion, for PTCL patients achieving CR1 following CHOP‐like induction chemotherapy, ASCT does not appear to improve progression‐free survival compared to active observation. This finding should be confirmed in a larger, prospective study. Am. J. Hematol. 91:672–676, 2016.
- 25 March 2016
- Published by Wiley in American Journal of Hematology
- Vol. 91 (7) , 672-676
Open AccessAutologous stem cell transplantation in first complete remission may not extend progression‐free survival in patients with peripheral T cell lymphomas
Patients with peripheral T cell lymphomas (PTCL) generally have a poor prognosis when treated with conventional chemotherapy. Consolidation with autologous stem cell transplantation (ASCT) has been reported to improve progression‐free survival. However, these studies have not compared consolidative ASCT with active observation in patients with PTCL achieving first complete remission (CR1) following induction chemotherapy. We conducted a retrospective analysis of PTCL patients treated at the University of Pennsylvania between 1/1/2007 and 12/31/2014. Patients with cutaneous T cell lymphoma, concurrent B cell lymphomas, and anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma (ALK‐positive ALCL) were excluded from the study. We compared progression‐free survival for patients who underwent ASCT in CR1 following CHOP‐like induction regimens and patients who underwent active observation during CR1. 48 patients met all inclusion and exclusion criteria and underwent either active observation (28 patients) or consolidative ASCT (20 patients) in CR1. The 1‐year cumulative incidence of relapse in the observation and ASCT groups was 50% (95% confidence interval [CI]: 30–67%) and 46% (95% CI: 23–67%), respectively (P = 0.55). Median progression‐free survival in the observation and ASCT groups was 15.8 and 12.8 months, respectively (log rank, P = 0.79). Estimated 3‐year progression‐free survival in the observation and ASCT groups was 37 and 41%, respectively. In conclusion, for PTCL patients achieving CR1 following CHOP‐like induction chemotherapy, ASCT does not appear to improve progression‐free survival compared to active observation. This finding should be confirmed in a larger, prospective study. Am. J. Hematol. 91:672–676, 2016.
- Open Access
- 16 November 2012
- Published by American Society of Hematology in Blood
- Vol. 120 (21) , 3710
Ricer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant
Abstract 3710
- 16 November 2012
- Published by American Society of Hematology in Blood
- Vol. 120 (21) , 3710
Open AccessRicer (Rituximab, Ifosfamide, Carboplatin, Etoposide, Revlimid) Is Well-Tolerated Salvage Regimen in First Relapse/Primary Refractory DLBCL Allowing Consolidation with Autologous Stem Cell Transplant
Abstract 3710
- Open Access
- 16 November 2008
- Published by American Society of Hematology in Blood
- Vol. 112 (11) , 4040
A Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
In vitro, bexarotene inhibits the proliferation of non-M3 AML cell lines and induces differentiation of leukemic blasts. Our previous phase I study in non-M3 AML showed evidence of leukemic response as manifested by reduction in bone marrow blast counts (15% response rate), improved platelet counts (41%) and improved neutrophil counts (26%). Based on these results, a phase II trial in non-M3 AML was initiated at the phase I MTD. In the current phase II trial, bexarotene (300mg/m2) was administered daily as monotherapy until disease progression or unacceptable side effects occurred. Fourteen patients have been enrolled: 8M/6F, median age 74 (range 20–83), 9 secondary AML (MDS or prior chemotherapy), 9 primary refractory or relapsed < 1 year after induction, 5 no prior induction chemotherapy, 5 requiring hydroxyurea at the time of enrollment for leukemic blast control, 4 prior allogeneic stem cell transplant, 12 blood transfusion dependent, 11 platelet transfusion dependent, and 8 neutropenic. Overall, no significant adverse events were noted. All patients received prophylactic antihyperlipidemic agents and achieved good lipid control. Two patients developed mild hypothyroidism related to bexarotene. Five patients were evaluable with bone marrow biopsy at 2 months: 1 50% reduction in absolute blasts, 1 SD and 3 PD. Similar to data from our prior phase I study, evidence of clinical activity was manifested as platelet count response in 1 patient and neutrophil increases attributable to bexarotene in 2 patients. When combining the results of our phase I experience (27 patients) with our phase II data (14 patients), there is a suggestion of increased activity in patients with 5q minus abnormalities with 4/7 (57%) benefiting (2 BM response, 4 neutrophil improvements and 1 platelet response). Conversely rates of clinical benefit were lower in patients with multiple (>3) cytogenetic abnormalities (2/13), relapse after stem cell transplant (1/9) or requiring hydroxyurea for peripheral blast control at the time of study enrollment (0/10). Bexarotene is very well tolerated at the dose level studied. Early evidence for clinical activity has been seen as exemplified by improvement in platelet count, increased neutrophil counts and decreased bone marrow blasts. In summary, we conclude that bexarotene is an active agent in a subgroup of patients with AML. Study enrollment continues with amended inclusion criteria to focus on patients more likely to benefit from treatment.
- 16 November 2008
- Published by American Society of Hematology in Blood
- Vol. 112 (11) , 4040
Open AccessA Phase II Trial of Bexarotene, a Retinoid X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
In vitro, bexarotene inhibits the proliferation of non-M3 AML cell lines and induces differentiation of leukemic blasts. Our previous phase I study in non-M3 AML showed evidence of leukemic response as manifested by reduction in bone marrow blast counts (15% response rate), improved platelet counts (41%) and improved neutrophil counts (26%). Based on these results, a phase II trial in non-M3 AML was initiated at the phase I MTD. In the current phase II trial, bexarotene (300mg/m2) was administered daily as monotherapy until disease progression or unacceptable side effects occurred. Fourteen patients have been enrolled: 8M/6F, median age 74 (range 20–83), 9 secondary AML (MDS or prior chemotherapy), 9 primary refractory or relapsed < 1 year after induction, 5 no prior induction chemotherapy, 5 requiring hydroxyurea at the time of enrollment for leukemic blast control, 4 prior allogeneic stem cell transplant, 12 blood transfusion dependent, 11 platelet transfusion dependent, and 8 neutropenic. Overall, no significant adverse events were noted. All patients received prophylactic antihyperlipidemic agents and achieved good lipid control. Two patients developed mild hypothyroidism related to bexarotene. Five patients were evaluable with bone marrow biopsy at 2 months: 1 50% reduction in absolute blasts, 1 SD and 3 PD. Similar to data from our prior phase I study, evidence of clinical activity was manifested as platelet count response in 1 patient and neutrophil increases attributable to bexarotene in 2 patients. When combining the results of our phase I experience (27 patients) with our phase II data (14 patients), there is a suggestion of increased activity in patients with 5q minus abnormalities with 4/7 (57%) benefiting (2 BM response, 4 neutrophil improvements and 1 platelet response). Conversely rates of clinical benefit were lower in patients with multiple (>3) cytogenetic abnormalities (2/13), relapse after stem cell transplant (1/9) or requiring hydroxyurea for peripheral blast control at the time of study enrollment (0/10). Bexarotene is very well tolerated at the dose level studied. Early evidence for clinical activity has been seen as exemplified by improvement in platelet count, increased neutrophil counts and decreased bone marrow blasts. In summary, we conclude that bexarotene is an active agent in a subgroup of patients with AML. Study enrollment continues with amended inclusion criteria to focus on patients more likely to benefit from treatment.